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Abstract
Background: Directly targeting therapeutic suicide gene to a solid tumor is a hopeful approach for cancer gene
therapy. Treatment of a solid tumor by an effective vector for a suicide gene remains a challenge. Given the lack
of effective treatments, we constructed a bifidobacterial recombinant thymidine kinase (BF-rTK) -ganciclovir (GCV)
targeting system (BKV) to meet this requirement and to explore antitumor mechanisms.
Methods: Bifidobacterium (BF) or BF-rTK was injected intratumorally with or without ganciclovir in a human colo320
intestinal xenograft tumor model. The tumor tissues were analyzed using apoptosis antibody arrays, real time PCR
and western blot. The colo320 cell was analyzed by the gene silencing method. Autophagy and necroptosis were
also detected in colo320 cell. Meanwhile, three human digestive system xenograft tumor models (colorectal cancer
colo320, gastric cancer MKN-45 and liver cancer SSMC-7721) and a breast cancer (MDA-MB-231) model were
employed to validate the universality of BF-rTK + GCV in solid tumor gene therapy. The survival rate was evaluated
in three human cancer models after the BF-rTK + GCV intratumor treatment. The analysis of inflammatory markers
(TNF-α) in tumor indicated that BF-rTK + GCV significantly inhibited TNF-α expression.
Results: The results suggested that BF-rTK + GCV induced tumor apoptosis without autophagy and necroptosis
occurrence. The apoptosis was transduced by multiple signaling pathways mediated by FasL and TNFR2 and mainly
activated the mitochondrial control of apoptosis via Bid and Bim, which was rescued by silencing Bid or/and Bim.
However, BF + GCV only induced apoptosis via Fas/FasL signal pathway accompanied with increased P53
expression. We further found that BF-rTK + GCV inhibited the expression of the inflammatory maker of TNF-α.
However, BF-rTK + GCV did not result in necroptosis and autophagy.
Conclusions: BF-rTK + GCV induced tumor apoptosis mediated by FasL and TNFR2 through the mitochondrial
control of apoptosis via Bid and Bim without inducing necroptosis and autophagy. Furthermore, BF-rTK + GCV
showed to repress the inflammation of tumor through downregulating TNF-α expression. Survival analysis results
of multiple cancer models confirmed that BF-rTK + GCV system has a wide field of application in solid tumor gene
therapy.
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Background
Cancer gene therapy approaches include the direct killing
of tumor cells by injecting a therapeutic gene into the
tumor cell or employing vaccine strategies to deliver an
immunomodulatory gene that stimulates the immune sys-
tem to recognize tumor antigens [1]. Bifidobacteria (BF)
are an important group of the human intestinal micro-
biota that exert a number of beneficial probiotic effects on
the host, including immunomodulation [2], antibacterial
activity [3], bacteriocin production [4], improvement of
the intestinal microbial balance [5], and a reduction of
inflammation [6]. BF is used in the health care and food
industries as a probiotic. BF can target to the hypoxic
environment of solid tumors and has been considered to
be an alternative strategy in tumor therapy or as a live
vaccine [7, 8].
The Herpes Simplex Virus thymidine kinase/ganciclovir
(HSV-TK + GCV) system is currently one of the best-
studied tumor suicide gene therapy systems [9–11]. When
expressed in tumors, TK converts the non-toxic precursor
GCV into GCV- 3-phosphate, a toxic substance that kills
tumor cells. Apoptotic signaling is initiated either through
extrinsic or intrinsic stimulation, resulting in the activa-
tion of caspases [12].
We previously found that bladder tumor growth was
significantly reduced in rats treated with BI-TK +GCV
after 15 days of treatment [10]. However, the mechanism
was unclear. In this research, we constructed a BF-specific
plasmid pBEX as an expression vector to express TK [8].
A colorectal cancer model was used to decipher the
molecular mechanism of BF-rTK +GCV (bifidobacterial
recombination thymidine kinase/ganciclovir) using a
human apoptosis antibody array kit in a murine cancer
model in vivo. Another three human cancer xenograft
models (gastric cancer MKN-45, liver cancer SSMC-7721
and breast cancer MDA-MB-231) were also established
for survival analysis after BF or BF-rTK +GCV intratumor
treatment.
Methods
Bacterial strains and growth conditions
Escherichia coli DH5α was used as the host for molecu-
lar cloning; pBEX was constructed by MA et al. [8] and
used as the expression vector in Bifidobacterium (BF).
The Bifidobacterium infantis strain (Collection in our
laboratory) was cultured in MRS broth (Difco) containing
0.25 % (w/v) L-cysteine. HCl (pH 7.0) at 37 °C under
anaerobic conditions. Ampicillin (50 mg/ml) was added to
both recombinant BF and E. coli strains when required.
Construction of BF-rTK + GCV suicide gene therapy
system
HSV TK gene (accession AB032875) was PCR amplified
and sub-cloned into pBEX at the BamH I and Sal I sites
with an artificial signal peptide. Potential recombinants
were first screened by bacterial colony PCR. The poten-
tial recombinant plasmid was transformed into compe-
tent B. infantis cells via electroporation, signatured
BF-rTK were used as TK producer cells, and verified by
DNA sequencing.
An intravenous (i.v.) gene therapy in nude mice indi-
cated that 1.0 × 106 cells/ml of BFTK was the highest
concentration with no adverse effects, whereas 1.0 × 104
cells/ml was the lowest effective concentration. At con-
centrations greater than 1.0 × 107 cells/ml, the i.v. injec-
tion resulted in venous embolisms and subsequent death.
Based on these results, 2.0 × 105 cells/ml were the dosage
of BF-rTK used in this study.
BF or BF-rTK (pBEX-tk) cells (0.5 ml, 2.0 × 105 cell/
ml) were prepared and mixed with 1.0 ml GCV (5.0 mg/
kg) respectively and PBS was added to adjust the final
volume to 2.0 ml. The negative control was 1.0 ml PBS
mixed with 1.0 ml GCV (5.0 mg/kg). Mixtures were
incubated at 37 °C for 1.0 h and further incubated for
10 min at 95 °C to stop the reaction. To identify whether
the rTK in BF-rTK cells was secreted expression, the
1.0 ml supernatant of BF-rTK culture was isolated by
centrifugation for 10 min at 12,000 rpm and incubated
with1.0 ml GCV (5.0 mg/kg) at 37 °C for 1.0 h and incu-
bated for another 10 min at 95 °C. The reactants were
centrifuged for 10 min at 12,000 rpm. Both supernatants
were analyzed by HPLC with an octadecylsilane che-
mically bonded silica column. The mobile phase ratio
was methanol: H2O (5:95) and the UV detection wave-
length was 252 nm.
Experimental animals
Mice (Balb/c-nu) and Balb/c mice were housed at the
Laboratory Animal Center of Chongqing Medical Univer-
sity (Chongqing, China). This study was carried out in
strict accordance with the recommendations in the Guide
for the Care and Use of Laboratory Animals of the
National Institutes of Health. The protocol was approved
by the Committee of the Ethics of Animal Experiments at
the Chongqing Medical University (SYXK2012-0001). All
procedures were performed under sodium pentobarbital
anesthesia, and the method of euthanasia was cervical
dislocation.
Cells and cell culture
Colo320 cell line was obtained from China Center for
Type Culture Collection (CCTCC GDC 042), gastric
cancer (MKN-45), liver cancer (SSMC-7721) and breast
cancer (MDA-MB-231) were obtained from Committee
of Type Culture Collection of Chinese Academy of
Sciences (CTCCCAS) and maintained in complete growth
medium: RPMI 1640 medium with 2 mM L-glutamine
adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L
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glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate,
90 %; 10 % fetal bovine serum. The cells were cultured in
100-mm culture dishes in a humidified, mixed environ-
ment of 37 °C and 5 % CO2.
Establishment of xenograft tumor models and
experimental groups
Mouse model of xenograft tumor was established by
injecting Colo320 cell (1.0 × 108 cells/ml) subcutaneously.
Twenty-four tumor-bearing nude mice (male, 3–4 week,
20 g/mouse) were randomly divided into five groups at
7 weeks post-inoculation: the normal control PBS group
(n = 3), GCV (n = 3), PBS +GCV (n = 6), BF + GCV (n =
6), and the BF-rTK +GCV group (n = 6). Each group was
once off directly given PBS, GCV, PBS +GCV, BF +GCV,
or BF-rTK +GCV through intratumor injections (BF or
BF-rTK was 1.0 × 106 cell/tumor, GCV was 5.0 mg/kg).
Three tumors were cut from sacrificed mice in each of the
last three groups (PBS +GCV, BF +GCV, or BF-rTK +
GCV) 48 h postinjection. From each cut out tumor, 20 %
was used for immunochemistry analysis and the other
80 % of the tumors of the three mice were mixed together
for protein array analysis (n =3). mRNA samples were
extracted from three tumors from the last three groups
for real time PCR analysis (n = 3). From the PBS and GCV
groups, mRNA samples were extracted from three tumors
for real time PCR analysis (n = 3).
Apoptosis array analysis
Total protein was extracted and prepared from the
colo320 tumor xenograft tissues and treated with PBS +
GCV, BF +GCV, and BF-rTK +GCV respectively and the
proteins concentration was normalized to 10 mg/ml,
following the protocol of RayBiotech human apoptosis
antibody array kit (Cat# AAH-APO-1-4). The results were
analyzed using the RayBiotech cytokine antibody arrays
Tool and the ratio of the significant differential expression
was considered to be more than 2.0 or less than 0.5.
Gene silencing and western blotting analysis
Colo320 cells were treated with commercial synthetic
small interference RNA (Bim394, Bid77, Bim394+ Bid77,
negative control) for 48 h respectively and then treated
with or without BF-rTK + GCV for 48 h (with three
replicates). Then the cells were lysed with NP40 buffer
(1 % NP-40, 0.15 M NaCl, 50 mM, Tris, pH 8.0) contai-
ning protease inhibitors (Sigma). Protein quantitation was
performed by BCA protein assay reagent (Pierce, USA).
Equal amounts of protein from the different groups were
denatured in SDS sample buffer and separated on 8–10 %
polyacrylamide-SDS gel based on the protein molecular
weight. Proteins were transferred to a polyvinylidene
difluoride membrane. The antibodies to Bim (abcam
32158), Bid (abcam 32060), GAPDH (cell signaling
technology, 14C10) were used to detect the target proteins,
followed by incubation with a secondary antibody conju-
gated with horseradish peroxidase. The proteins of interest
were detected using SuperSignal West Pico Chemilumines-
cent Substrate kit.
Immunohistochemistry staining
Immunohistochemistry (IHC) of XIAP (E3 ubiquitin-
protein ligase XIAP), FADD (FAS-associated death domain
protein), APAF-1 (apoptotic protease-activating factor 1)
and cleaved Caspase-3 was conducted on five colo320
tumor xenograft tissues treated by PBS, GCV (resolved in
PBS solution), BF, BF +GCV and BF-rTK +GCV, respec-
tively (with three replicates). Retrieved tissues were fixed,
decalcified in 10 % formalin and embedded in paraffin 24 h
posttreatment. Serial sections of the embedded specimens
were stained with hematoxylin and eosin (H & E). The
fixed tissues of colo320 intestinal tumor were blocked and
incubated with XIAP antibody (ab21278, abcam), FADD
antibody (ab52935), APAF-1 antibody (ab32372) and
cleaved Caspase-3 antibody (ab52293). After being washed,
tissues were incubated with biotin-labeled secondary anti-
body for 30 min, followed by incubation with streptavidin-
HRP conjugate for 20 min at RT. The presence of the
expected protein was visualized by DAB staining and exa-
mined under a microscope. Stains with control IgG were
used as negative controls.
Immunofluorescence
Immunofluorescence staining analysis of FasL (Fas ligand)
expression in mouse colo320 tumor xenograft tissues was
performed (with three replicates). The slides were then
incubated with primary antibody diluted in PBS contain-
ing 1 % BSA for 16 h at 4 °C. The primary antibodies used
were as follows: anti-FasL antibody (ab68338, 1:500). After
washing three times in PBS, Alexa Fluor 55 5-conjugated
anti-rabbit IgG (Invitrogen, Grand Island, NY) was added
in PBS with 1 % BSA for 1 h. In the final washes, 6-
diamidino-2-phenylindole (DAPI) (Sigma) was added and
used as a counterstain for nuclei. Fluorescence images
were acquired using a Zeiss Axioimager microscope.
RNA isolation and quantitative RT-PCR
The Caspase-3 downstream effectors (Rock-1 (Rho-asso-
ciated protein kinase 1), Cad and Acinus (apoptotic
chromatin condensation inducer in the nucleus)) were
not contained in the apoptosis antibody array. In order
to make up for the above mentioned missing in the
apoptosis antibody array, total RNA was extracted from
three colo320 tumor xenograft tissues from each group
treated by PBS + GCV, BF + GCV and BF-rTK + GCV
respectively, using TRIzol reagent (Invitrogen). The total
RNA was applied to an RNase column (Qiagen, Venlo,
Netherlands) for further purification and treated with
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DNase following the manufacturer’s protocol. cDNA was
synthesized from 1 μg of total RNA using the SuperScript
III reverse transcriptase kit (Invitrogen) resulting in a
final volume of 20 μl. Primers were designed with the
IDT SCI primer design tool (Integrated DNA Technolo-
gies, San Diego, California). Quantitative real time PCR
(qRT-PCR) experiments were performed with Bio-Rad
MJ MiniOption Real Time PCR System in triplicate and
the data analysis was carried out by the CFX manager
software version 1.5. The PCR data were normalized to
GAPDH expression. The sequences of each primer pair
were listed in Table 1.
Survival rate analysis of the other three kinds of tumor
cell lines of nude mouse models in BF-rTK + GCV
intratumor treatment
The other three tumor cell lines included gastric cancer
(MKN-45), liver cancer (SSMC-7721) and breast cancer
(MDA-MB-231). The nude mouse models of xenograft
tumor (diameter ≥3.5 mm) were established by injecting
the three different kinds of cancer cells (1.0 × 108 cells/
ml) subcutaneously. Each positive group contained six
nude mice (male, 3–4 week, 20 g/mouse) and when the
xenograft tumor diameter was greater than 3.5 mm,
BF-rTK (1.0 × 106 cell/mouse) was intratumorally given
twice in 5 days. GCV (5.0 mg/kg, n = 6) was given via
intramuscular injections every day during the five days.
Each negative control group of six nude mice bearing the
xenograft tumor were raised without any injections (Ctrl,
n = 6). After the second BF-rTK injection (5 d), all mice
were raised without any treatment. The surviving mice
were counted every day. The data at the 1 d, 5 d, 17 d, 19
d, 21 d, 24 d, 27 d, 30 d, 35 d and 37 d were used to
analyze survival rate. The significant difference was
measured by p value.
Analysis of inflammatory marker in tumor tissue
treatment by BF-rTK + GCV
IHC of TNF-α (tumor Necrosis Factor 2 A) was performed
on five colo320 tumor xenograft tissues treated by PBS,
GCV (resolved in PBS solution), BF, BF +GCV and BF-
rTK +GCV, respectively (with three replicates). The follow-
ing process was the same as the IHC assay of the apoptosis
relative markers described previously. The presence of the
TNF-α was visualized by DAB staining and examined
under a microscope. Stains with control IgG were used as
negative controls.
Effect of BF-rTK + GCV on necroptosis and autophagy
protein expression
Necroptosis and autophagy relative protein markers inclu-
ding RIP-1 (Zinc metalloprotease Rip1), ATG5 (autophagy
protein 5) and Beclin-1 were analyzed by western blot in
colo320 intestinal tumor cell treated with BF + GCV or
BF-rTK + GCV. The antibodies of RIP-1 (BA0346-2)
and Beclin-1 (BA3123-2) were purchased from Boster
(Wuhan, China) and the antibodies of ATG5 (10181-2-AP)
were purchased from Proteintech (Wuhan, China).
Statistical analysis
Statistical analysis was performed using SPSS-17.0 soft-
ware. Data were analyzed using one-way analysis of vari-
ance and Tukey’s HSD test was applied as a post hoc test
if statistical significance was determined. Statistical sig-
nificance for the two groups was assessed using Student’s
t-test. The probability level at which differences were
considered significant was p < 0.05.
Results
BF-rTK phosphorylates GCV
To evaluate the activity of recombinant TK (rTK) expressed
in Bifidobacterium (BF), GCV was treated with BF-rTK
recombinant and the result showed that 39 % of GCV was
phosphorylated by rTK after co-culture for 1 h at 37 °C,
and measured using HPLC (Fig. 1b, c, d).
To test that functional rTK was secreted from the
recombinant BF cells, the GCV was treated with the
supernatant of BF-rTK culture and the result showed that
GCV was phosphorylated obviously. The result indicated
that the rTK could be secreted by BF (Fig. 1e). However,
the level in BF supernatant was less than 43 % (p < 0.05).
BF induces apoptosis via Fas/FasL signal pathway and
increases Caspase-3, −8 and P53 protein expression levels
In order to evaluate the antitumor activity of bifidobacte-
rium as a gene transfer vehicle as fully as possible, we
quantitatively analyzed the colo320 xenograft tumor
tissues. This was done by intratumor administration of BF
+GCV instead of GCV (in PBS solution) using a RayBio-
tech human apoptosis antibody array kit containing 43
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human apoptotic factors. The results showed that 14
differential proteins expression was upregulated and
therefor doubled unlike the expression in those subjected
to PBS +GCV (Table 2). Specifically, the expression of Fas
(tumor necrosis factor receptor superfamily member 6,
TNFRSF6) and FasL was increased more than 2-fold and
the changed downstream proteins of Fas/FasL were
divided into two groups: four anti-apoptosis proteins
(Bcl-2 (apoptosis regulator Bcl-2), Bcl-w, IGF-1 (insulin-
like growth factor I), IGF-2) and eight pro-apoptosis
proteins (Bad (Bcl2-associated agonist of cell death), Bax
(apoptosis regulator BAX), Bim (Bcl-2-like protein 11),
Caspase-3,-8, HtrA2 (serine protease HTRA2, mitochon-
drial), etc.; Table 2). The anti-apoptosis proteins were
increased more than 5.0-fold. The other eight pro-
apoptosis proteins increased from 2.22-fold (FasL) to
8.87-fold (Caspase-8) after BF treatment (Table 2). The
ratio of Bax/Bcl-2 was 0.60 in BF treatment. Another
characteristic change was a 2.40-fold increase in p53. The
total ratio of pro-apoptosis to anti-apoptosis proteins was
2.02-fold. IGF-1 and IGF-2 (insulin-like growth factor)
increased more than 5-fold, however, their inhibitor,
IGFBPs (IGF binding protein), showed no significant
variation in BF + GCV intratumor-treated animals. The
downstream effecter, Caspase-3, increased more than
6.56-fold. However, the typical mitochondrial control
signal molecule, Cytochrome C (Cyto C), was not signifi-
cantly changed compared with the PBS + GCV treatment.
GCV could not be phosphorylated by Bifidobacterium,
the variation of Fas/FasL and the downstream proteins
were results of the growth of BF in the tumor. Therefore,
the results suggested that bifidobacterium itself (not
GCV) induced cancer cell apoptosis via Fas/FasL signa-
ling pathway without mitochondrial alteration and upre-
gulated P53 expression.
Effect of BF-rTK/GCV on apoptosis pathway protein
expression
The different effects of BF-rTK + GCV and BF + GCV
on antitumor activity were also evaluated by the RayBio-
tech human apoptosis antibody array kit. The results
showed that 30 differential proteins in the BF-rTK +GCV
intratumor-treated tumor tissues were upregulated more
than 2-fold compared with the BF +GCV intratumor-
treated group (Table 3). Specifically, 23 pro-apoptosis
associated proteins were increased from 2.48-fold (tumor
necrosis factor-β, TNF-β) to more than 23.05-fold (Hsp70).
Five anti-apoptosis proteins (Bcl-2, Bcl-w, Livin (baculoviral
IAP repeat-containing protein 7), IGF-1, IGF-2) were mark-
edly increased from 2.18-fold (IGF-1) to 15.45-fold (Bcl-w)
as compared to the BF +GCV group. However, two anti-
apoptosis proteins were significantly decreased (XIAP, 0.22-
Fig. 1 Construction and verification of thymidine kinase expression system and GCV phosphorylated by rTK in Bifidobacterium infantis. HPLC detected
the concentration of GCV treated with PBS, BF and BF-rTK for 1 h at 37 °C respectively. The supernatants were analyzed by HPLC with octadecylsilane
chemically bonded silica column. The mobile phase was methanol + H2O (5 + 95) and UV detection wavelength was 252 nm. a PCR detection of rTK
gene in BF-rTK (lane 1 & 2) and BF (lane 3). b PBS + GCV. c BF-rTK + GCV. d BF + GCV. e The BF cell lysis and BF culture supernatant were analyzed by
HPLC after incubation with GCV. The BF-rTK supernatant assay suggesting that rTK expressed in BF-rTK cells can be secreted into supernatant
(*P < 0.05 statistically significant when comparing treated versus control)
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fold, Survivin, 0.28-fold). The total of pro-/anti-apoptosis
ratio was 5.20-fold and the ratio of Bax/Bcl-2 was 1.06 in
BF-rTK +GCV treatment (Table 3). The P53 protein level
was not significantly changed in BF-rTK +GCV group. The
IGFs (IGF-1, IGF-2) inhibitors, IGFBP3-6 (IGF binding
protein), were increased from 7.39-fold to 8.93-fold as
compared to the BF +GCV treated tumors and the ratio of
IGFBPs/IGFs was 3.42-fold. The results indicated that
BF-rTK +GCV induced the increased expression of many
pro-apoptosis associated proteins.
Silencing Bid or/and Bim expression impairs apoptosis
caused by BF-rTK + GCV
Bid and Bim are two critical signaling proteins located
downstream of Fas/FasL (Fas/Fas ligand) and TNF-β/
TNFR2 (TNF receptor 2) signal pathway. In order to
evaluate their functions in apoptosis, Bid or/and Bim were
silenced by commercial synthetic siRNA. The cell density
was statistically increased in siBim, siBid, or siBim plus
siBid treatments together with BF-rTK +GCV unlike in
the negative control group which only received BF-rTK +
GCV treatment (Fig. 2a). The western blot result showed
that Bim (Fig. 2b, left) or Bid (Fig. 2b, right) expression
was diminished and/or undetectable in the siRNA Bim394
and Bid77 compared to cells infected with the negative
control siRNA. The cell density was dramatically decreased
in cells treated with BF-rTK +GCV (Fig. 2a). However, the
cell density was significantly increased in siBim, siBid, or
siBim plus siBid treatments together with BF-rTK +GCV
compared to the group which received BF-rTK +GCV
treatment alone (Fig. 2a). Together, these results demon-
strated that inhibiting Bim or/and Bid protein expression
Table 2 Apoptosis associated proteins change in group
BF + GCV
Gene PBS + GCV BF/GCV Ratio
Bad 335.83 982.79 2.93
Bax 516.54 1567.29a 3.03
Bim 192.61 1488.21 7.73
Bcl-2 192.61 968.65a 5.03
Bcl-w 192.61 1342.08 6.97
IGF-1 192.61 984.35 5.11
IGF-2 192.61 997.97 5.18
Caspase 3 192.61 1262.99 6.56
Caspase 8 192.61 1708.19 8.87
HtrA2 192.61 1314.83 6.83
Fas 538.63 1201.19 2.23
FasL 521.06 1154.57 2.22
P53 489.92 1175.53 2.40
P27 620.96 1405.44 2.26
The boldface letters were anti-apoptosis proteins and the others were
apoptosis proteins
aThe ratio of Bax/Bcl-2 is 0.60
Up-regulation of fourteen differential proteins expression was more than doubled
in the BF +GCV group unlike the expression in the PBS +GCV group. To summarize,
the anti-apoptosis proteins were increased more than 5.0-fold. The total ratio of
pro-apoptosis to anti-apoptosis proteins was 2.02-fold and the ratio of Bax/Bcl-2
was 0.60. The typical mitochondrial control signal molecule, Cytochrome C (Cyto C),
was not significantly changed in group BF +GCV. The results suggested that
bifidobacterium itself (not GCV) induced cancer cell apoptosis via Fas/FasL signaling
pathway without mitochondrial alteration and up-regulated P53 expression
Table 3 Apoptosis associated proteins change in group
BF-rTK + GCV.
Gene BF/GCV BF-rTK/GCV Ratio
Bad 100.03 895.52 8.95
Bax 100.15 1155.50a 11.54
Bid 700.90 3450.87 4.92
Bim 100.38 1292.41 12.88
Bcl-2 100.25 1093.11a 10.90
Bcl-w 100.5 1552.42 15.45
XIAP 463.48 100.25 0.22
Survivin 1047.24 296.30 0.28
Livin 100.38 605.98 6.04
Caspase 3 100.88 1651.20 16.37
Caspase 8 100.57 1256.01 12.49
Cytochrome C 100.35 1004.71 10.01
HtrA2 100.76 1578.36 15.67
c-IAP2 229.05 779.93 3.41
Fas 100.87 789.76 7.83
FasL 100.35 316.53 3.15
TNF-beta 568.88 1408.11 2.48
TRAILR-1 277.23 1306.83 4.71
TRAILR-2 138.21 1055.52 7.64
TRAILR-3 100.35 411.89 4.11
IGF-1 100.32 723.87 7.22
IGF-2 100.77 219.51 2.18
IGFBP-3 142.73 1173.35 8.22
IGFBP-4 96.06 857.88 8.93
IGFBP-5 100.32 760.31 7.58
IGFBP-6 100.33 741.30 7.39
Hsp60 100.35 2263.01 22.56
Hsp70 100.89 2325.38 23.05
Hsp27 100.38 1009.85 10.06
P21 472.51 1305.01 2.76
The boldface letters were anti-apoptosis proteins and the others were
apoptosis proteins
The BF value was independent of Table 2 and they are read from two
different films
aThe ratio of Bax/Bcl-2 is 1.06
Thirty differential proteins were up-regulated more than 2-fold in group BF-rTK +
GCV compared with the BF + GCV intratumor-treated group. To summarize,
twenty-three pro-apoptosis associated proteins were increased from 2.48-fold
(TNF-β) to more than 23.05-fold (Hsp70). The total of pro-/anti-apoptosis ratio
was 5.20-fold and the ratio of Bax/Bcl-2 was 1.06 in group BF-rTK + GCV. The
results indicated that BF-rTK + GCV induced the increased expression of many
pro-apoptosis associated proteins
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could prevent a great amount of cells from apoptosis in-
duced by BF-rTK +GCV.
Immunohistochemistry (IHC) analysis of active-Caspase-3
and the upstream proteins
The up-regulated TNF-β, TNFRSFs (tumor necrosis factor
receptor superfamily members) and Cytochrom C (Cyto
C) in apoptosis antibody array implied that the cancer cell
apoptosis was triggered by death receptors and transduced
from a Cyto C/Apaf-1/Caspase-9 to Caspase-3 pathway
linked to mitochondria. To confirm the hypothesis, sev-
eral key proteins were analyzed by IHC. The results
showed that the cleaved-Caspase-3 (active molecular) up-
regulated expression significantly. Meanwhile, the upstream
protein, APAF-1, was also upregulated which was crucial
for Caspase-3 activation. The FADD was upregulated sig-
nificantly which was essential to Caspase-8 activation and
then transduced signals to mitochondrion and/or Caspase-
3. In addition, IHC assay also confirmed that XIAP
(Caspase-3 inhibitor) expression decreased in BF-rTK +
GCV treatment recipient tissues (Fig. 3a and e). FasL is a
stimulator that activates FADD through Fas. FasL immu-
nostaining also revealed that FasL expression was increased
significantly in colo320 tumor xenograft tissue intratu-
morally treated with BF-rTK +GCV (Fig. 4e and f). The
results suggest that BF-rTK +GCV triggered many TNF
superfamily receptor mediated signal transduction path-
ways (e.g. Fas, TNFR2 and TNFRSFs (DR4 (death recep-
tor 4, TNFRSF10A), DR5 (TNFRSF10B)) and the signals
were transduced through mitochondrial associated caspase-
3 pathway.
Fig. 2 Silencing Bim or/and Bid rescues cancer cells from apoptosis induced by BF-rTK + GCV. a Cell imagines and quantitative analysis of the cell
density by cell count. (Negative control vs BF-rTK + GCV+ Negative control; BF-rTK + GCV+ Negative control vs BF-rTK + GCV + siBim, BF-rTK + GCV+
Negative control vs BF-rTK + GCV + siBid, BF-rTK + GCV+ Negative control vs BF-rTK + GCV + siBim + siBid). b Western blot analysis of Bim and Bid
protein expression. Colo320 cells were treated with silencing Bim394, Bid 77 or with a control silencing siRNA for 48 h, and then cells were treated with
or without BF-rTK + GCV for 48 h. Cell protein was extracted to detect Bim and Bid expression. Bim or Bid expression was silenced by Bim394 and Bid
77. c Quantification of protein levels from immunoblots as in b. The protein levels of Bid and Bim were normalized to GAPDH (*P < 0.05 statistically
significant when comparing treated versus control; #P > 0.05 statistically no significant when comparing treated versus control)
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Gene transcription of Caspase-3 downstream effectors is
significantly up-regulated by BF-rTK/GCV in colo320
intestinal tumor
Caspase-3 played a crucial role in the TNF superfamily
receptor induced apoptosis signaling pathway. The active
Caspase-3 induced several effectors activity through
three different pathways and induced apoptosis. In order
to evaluate the level and type of Caspase-3 downstream
pathway activated by BF-rTK +GCV, three Caspase-3
effectors genes (Rock-1, Cad and Acinus) were detected
Fig. 3 BF-rTK + GCV regulates colo320 tumor xenograft tissues apoptosis, up- regulates FADD, APAF-1 and cleaved caspase-3, and down- regulates
XIAP. H&E (hematoxylin-eosin staining) and immunohistochemistry were performed using the specific antibody of cleaved caspase-3, apaf-1, FADD
and XIAP antibody and the xenograft tumor tissues treated with PBS, GCV, BF, BF + GCV and BF-rTK + GCV (200×, n = 3). a Representative histologic
sections of H&E staining. The yellow color showed positively stained cells by cleaved caspase-3, apaf-1, FADD and XIAP antibody. b, c, d and e IOD
SUM of positive cells was compared among PBS, GCV, BF, BF + GCV and BF-rTK + GCV mice. Data were given as means and 95 % confidence intervals.
Asterisks indicate data that were significantly different from PBS, GCV groups and BF, BF + GCV groups, or both BF, BF + GCV groups and BF-rTK + GCV
groups (*P < 0.05 statistically significant when comparing treated versus control)
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using qRT-PCR. The results showed that BF-rTK +GCV
triggered Rock-1, Cad and Acinus transcription to increase
significantly more than that of the in vivo BF +GCV treat-
ment group (3 ~ 21-folds; Fig. 5). The Rock-1 induced cell
shrinkage and membrane blebbing, CAD induced DNA
fragmentation and Acinus induced chromatin conden-
sation and finally resulted in cell apoptosis. Therefore, the
data suggested that Caspase-3 is a key connecting link
between the preceding and the following of BF-rTK +
GCV induced apoptotic signaling pathway.
BF-rTK + GCV induces cell apoptosis through TNFR2
signaling in vitro
To elucidate the type of TNFs and TNFRs interaction in
the tumor cell apoptosis induced by BF-rTK +GCV, TNF-
α, TNF-β, TNFR1 and TNFR2 were analyzed by western
blot in colo320 intestinal tumor cell. The novelty found in
this work was that BF-rTK +GCV triggered TNF-β (not
TNF-α) to induce cancer cell apoptosis in vitro TNFR2
(not TNFR1) (Fig. 6).
To evaluate the universality of BF-rTK +GCV induced
apoptosis via TNFR2 mediated signaling pathway, gastric
cancer cell (MKN-45) was employed as another model.
The apoptosis related proteins, namely, FAS, FADD,
active-Caspase-8, TNFR1, TNFR2, DR4 and DR5 were
tested with western blot. These results confirmed that BF-
rTK +GCV universally induced solid tumor cell apoptosis
viaTNFR2 mediated signaling pathway (Fig. 7).
BF-rTK + GCV prevented death of a wide variety of solid
tumor mice models
In order to evaluate the universality of BF-rTK +GCV
antitumor activity, the survival rate after two intratumor
BF-rTK +GCV injections of three different kinds of
human solid tumor models (gastric cancer, liver cancer
and breast cancer) were analyzed. The results showed that
BF-rTK +GCV prevented more than 83 % of tumor bear-
ing mice from death of liver cancer after the mere admi-
nistration of two doses of intratumor injections. The
protection rates were 50 % in the gastric cancer group and
breast cancer group during a period of 30 days (Fig. 8a).
The tumor growth was inhibited and the treated tumors
were smaller on day 32 after treatment (Fig. 8b). There
was significant difference between the groups of BF-rTK
+GCV treatment and their controls in each of cancer
models (p < 0.05). However, the statistical difference of BF-
rTK +GCV treatment effects between the three groups
was no significant (P > 0.05). The results suggested that BF-
rTK +GCV effectively prevented mice from death in mul-
tiple human solid tumor models.
Fig. 4 Analysis of FasL in the intestinal colo320 xenograft cancer tissues (n = 3) by immunofluorescence. Red is positive for expression of Fasl protein.
a PBS, b GCV, c BF, d BF + GCV, e BF-rTK + GCV (200×). The nuclei were stained with DAPI. f Quantitative analysis of the fluorescence intensity from
immunofluorescence. (*P < 0.05 statistically significant when comparing treated versus control)
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BF-rTK + GCV inhibits inflammatory marker, TNF-α,
expression
The IHC of TNF-α result showed that BF-rTK + GCV
administration (i.v) significantly down-regulated TNF-α
expression (Fig. 9). The result suggested that BF-rTK +
GCV administration (i.v) inhibits the expression of the
major tumor inflammatory marker, TNF-α, in tumor
microenvironment. Correspondingly, the BF-rTK +GCV
treatment did not increase the expression of TNFR1
(TNF-α receptor type 1) both in colo320 intestinal tumor
cell (Fig. 6) and in gastric cancer cell (MKN-45) (Fig. 7).
Therefore, the feature of inflammatory inhibition might be
taken advantage of for BF-rTK +GCV cancer treatment.
Effects of BF-rTK + GCV on necroptosis and autophagy
associated protein expression
Besides apoptosis, necroptosis and autophagy are two
basic cell death pathways [13, 14]. In order to elucidate
the effects of BF-rTK/GCV on necroptosis or/and autoph-
agy in cancer cells, the typical molecular marker proteins
of necroptosis and autophagy were analyzed with western
blot. The results showed that RIP-1 protein expression
was slightly down-regulated in colo320 cell treated by BF-
rTK +GCV. RIP-1 is a critical mediator of necroptosis.
The result suggested that BF-rTK +GCV treatment had
no effect on necroptosis (Fig. 9, P > 0.05). We further
explored whether BF-rTK +GCV can promote or decrease
the autophagy related proteins (ATG5, Beclin-1) expres-
sion. Similarly, the western blot results also showed no
significant change. Therefore, BF-rTK +GCV treatment
also had no effect on autophagy (Fig. 10).
Fig. 5 Caspase-3 downstream apoptosis-related genes are up-regulated
in BF-rTK + GCV induced apoptosis. a–c Colo320 intestinal xenograft
tumor tissues treated by GCV, BF + GCV and BF-rTK + GCV were collected
and RNA was extracted from tumor tissues (n= 3). Gene transcription of
Rock-1 (a), Acinus (b) and Cad (c) were analyzed by qRT-PCR using
specific primers. All values were normalized to GAPDH as an internal
control and were expressed relative to tumors treated with GCV in
each case (*P< 0.05 statistically significant when comparing treated
versus control)
Fig. 6 Analysis of TNF and TNFR expressions in BF-rTK + GCV treatment of colo320 intestinal tumor. a The protein samples were extracted from
colo320 cells treated by PBS, BF + GCV, and BF-rTK + GCV, respectively. The TNF-α, TNF-β, TNFR1 and TNFR2 levels were analyzed with western
blot. The gels were run under the same experimental conditions. b Quantitative analysis of TNF-α, TNF-β, TNFR1 and TNFR2 (*P < 0.05 statistically
significant when comparing treated versus control; #P > 0.05 statistically no significant when comparing treated versus control)
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Fig. 7 Analysis of apoptosis associated proteins expression in different kinds of cancer cell lines treated by BF-rTK + GCV. a The gastric cancer cell
MKN-45 proteins were extracted and some typical apoptosis associated proteins (FAS, FADD, DR4, DR5, TNFR1 and TNFR2) were analyzed by western
blot with specific antibodies. b Quantitative analysis of FAS, FADD, DR4, DR5, TNFR1 and TNFR2 (*P < 0.05 statistically significant when comparing
treated versus control; #P > 0.05 statistically no significant when comparing treated versus control)
Fig. 8 Survival rate analysis of a wide variety of solid tumor mice models in BF-rTK + GCV treatment. a Three different kinds of human solid tumor
models (gastric cancer MKN-45 (GCA), breast cancer MDA-MB-231 (BCA) and liver cancer SSMC-7721 (LCA)) were established by injecting cancer
cells (1.0 × 108 cells/ml) subcutaneously. Each positive group contained six nude mice that had BF-rTK + GCV intratumorally injected twice in five
days after the xenograft tumor diameter was more than 3.5 mm (BF-rTK + GCV was 1.0 × 106 cell/tumor, n = 6) and GCV (5.0 mg/kg) was given as an
intramuscular injection every day during the five days. Each negative control group of six nude mice bearing xenograft tumors were raised without
any injections (Ctrl, n = 6). After the second BF-rTK + GCV injection for positive groups, all mice were raised without any treatment. The mice that
survived were counted every day. The data at the 1 d, 5 d, 17 d, 19 d, 21 d, 24 d, 27 d, 30 d, 35 d and 37 d postinjection were used to analyze
survival rate (*P < 0.05). b On 32 d postinjection, the tumors were isolated from three different groups and the tumor size was compared between
the control and treatment groups
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Fig. 9 BF-rTK inhibits intestinal cancer tissues TNF-α expression. Immunohistochemistry using the specific antibody of TNF-α antibody and the
xenograft tumor tissues treated by PBS, GCV, BF, BF + GCV and BF-rTK + GCV (200×, n = 3). The yellow color shows positively stained cells by TNF
antibody. IOD SUM of positive cells was compared among PBS, GCV, BF, BF + GCV and BF-rTK + GCV mice. Data are given as means and 95 %
confidence intervals. Asterisks indicate data that are significantly different from PBS, GCV groups and BF, BF + GCV groups, or both BF, BF + GCV
groups and BF-rTK + GCV groups (*p < 0.05 statistically significant when comparing treated versus control)
Fig. 10 Western blot analysis of necroptosis and autophagy associated proteins expression in BF-rTK + GCV treatment intestinal tumor of colo320.
a Colo320 intestinal tumor cells were treated by PBS, BF + GCV or BF-rTK + GCV, respectively. The necroptosis and autophagy associated proteins
(RIP-1, ATG5, Beclin-1) were detected by specific antibodies from colo320 cell 48 h post-treatment. The cropped gels were run under the same
experimental conditions. b Quantitative analysis of RIP-1, ATG5 and Beclin-1 (#P> 0.05 statistically no significant when comparing treated versus control)
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Taken together, the first significance of the findings was
that BF-rTK +GCV induced tumor apoptosis through
multiple signaling pathways mediated by two Fas/FasL
and TNF-β/TNFR2 and mainly activated the mitochon-
drial control of apoptosis via Bid and Bim. Caspase-3
played a crucial role as a hub and transduced apoptosis
signals through three different pathways via Rock-1, CAD
and Acinus. The second significance of the findings was
that the results of multiple cancer lines analysis confirmed
that BF-rTK +GCV system treatment prevented tumor
bearing mice from death in a wide variety of solid tumors
and the mechanism of apoptosis had universality. The
third significance of the findings was that BF-rTK +GCV
system treatment had no effect on tumor necroptosis or
autophagy.
Discussion
Conventional suicide gene therapy vectors used in cancer
cases are typically based on herpes simplex virus or
adenovirus [15, 16]. There are HSV-TK +GCV-mediated
gene therapy systems and adenovirus-mediated gene the-
rapy systems and lentivirus TK +GCV gene therapy for
lung cancer treatment [9, 17–19]. It is clear that GCV is
phosphorylated by the HSV1-TK to GCV monopho-
sphate, and further to GCV di- and triphosphate and
incorporated into proliferating tumor cell DNA, which
causes DNA chain termination and induces tumor cell
apoptosis [17]. The major obstacle for wide clinical appli-
cation of this approach is the insufficient amounts of the
suicide gene delivered into the target tumor tissue by
virus-based vectors [17]. For example, the multiplicity of
infection (MOI) of adenovirus-Rous sarcoma virus-
thymidine kinase is no less than 66 in MDAH-2774
ovarian cancer cells after acyclovir treatment [20].
Bifidobacterium (BF) is a non-pathogenic, non-toxic,
and strictly anaerobic gram-positive bacterium and can
target the hypoxic environment of solid tumors for its
anerotaxis [7, 10, 21]. In this research, we revealed the
differences in mechanisms of BF +GCV and BF-rTK +
GCV systems in inducing colo320 cell apoptosis in detail.
Compared with virus-mediated vectors, the superiority of
BF-rTK recombinant is that it does not invade the tumor
cell and the rTK can be secreted outside of BF and thereby
phosphorylates GCV. The phosphorylated GCV diffuses
in the tumor tissue and functions its antitumor activity
and the process remains independent of tumor cellular
bio-systems. That means, BF-rTK does not target a single
cancer cell, but the solid tumor as a whole. However,
recombinant viruses (e.g. adenovirus-Rous sarcoma virus-
thymidine kinase) have to infect and kill single cancer cells
one by one. The bacteria engulfing is not necessary for
BF-rTK +GCV system. The BF-rTK recombinant can be
quickly reproduced outside cancer cells independently.
Therefore, BF can deliver sufficient suicide genes into the
target tumor tissue without MOI limitation.
Death receptors (DRs) are the members of TNF re-
ceptor superfamily including Fas/FasL, TNFRSF (DR4
(TNFRSF10A), DR5 (TNFRSF10B)) and TNF receptor
(TNFR1, 2) [22, 23]. TNF-β, lymphotoxin α, is generally
described as an inflammatory and immune response factor
and is signaled via TNFR1 and TNFR2. TNF-β is involved
in the processes of inducing cell apoptosis when it is
signaled by TNFR1. It then subjects a wide range of tumor
cells to cytotoxicity [24]. However, there are few reports
about TNF-β inducing cancer cell apoptosis via TNFR2 to
date.
Compared to BF +GCV intratumor treatment, BF-rTK
+GCV treatment increased four IGFBPs expression
(Table 3). IGFBPs down regulate the activity of IGFs [18],
and promote apoptosis by modulating the expression of
apoptosis-specific genes such as Bcl-2 and Bax [24–26].
IGFBP-6 has a high affinity for binding IGF-2 and is able
to inhibit the growth of various cancer cells and activated
apoptosis pathways as an IGF-antagonist [27–29]. The
Bax/Bcl-2 ratio in BF-rTK +GCV was increased 1.7-fold
compared to BF +GCV treatment (Tables 2 and 3), which
lead to the activation of the caspase cascade. However,
IGFs promote a shift in the expression of the Bcl-2 family
and prevent glucose-induced Cyto C release, which is
directionally blocked activation of the terminal apoptosis
program and exhibits a decrease in the Bax/Bcl-2 ratio
[30]. That could explain why no detectable Cyto C was
found in the BF +GCV group. Therefore, the pro-apoptosis
proteins overwhelmed the anti-apoptosis proteins and the
final results were tilted the balance toward apoptosis
(Tables 2 and 3).
XIAP, c-IAP2, Livin and Survivin belong to the inhibitor
of apoptosis family (IAP) with typical BIR (baculovirus
IAP repeat) domain. IAP directly binds to Caspases as well
as neutralization of Smac and further activates down-
stream anti-apoptotic cascades [30]. However, the inhibi-
tory effect of Livin on Caspase-3 and Caspase-9 is much
weaker compared to that of XIAP [31].
Bid and Bim are two important upstream target proteins
up-regulated by Fas/FasL signaling and TNFR signaling in
the mitochondrial control of apoptosis. Bid and/or Bim
SiRNA treatment prevented colo320 intestinal tumor cells
from apoptosis induced by BF-rTK +GCV in vitro as
expected. The results confirmed that Fas/FasL signaling
and TNFR signaling are principal pathways in BF-rTK +
GCV induced colo320 intestinal tumor apoptosis in vivo.
The gene silencing results suggested that these changes
are causative rather than simply secondary effects of
BF-rTK + GCV treatments.
Inflammation was identified as the seventh feature of
cancer [32]. Our data showed that BF-rTK +GCV system
inhibited both TNF-α and its receptor, TNFR1, expression
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in tumor tissue, which indicated that BF-rTK +GCV inhi-
bited inflammation induced by TNF-α/TNFR1 pathway. It
was a synergistic effect of the tumor therapy. TNF-α is
known to play an important role in various aspects of
tumor progression. It was reported that TNF-α may
promote breast cancer cell migration by inducing activa-
tion of the MAPK/ERK signaling pathway [33]. In another
study, TNF-α was found to stimulated prostate carcino-
genesis in chemically induced mice by activation of the
AKT/mTOR and NFkB pathway [34]. Evidence suggested
that the anti-inflammatory treatment prior to chemothe-
rapy suppressed the acquisition of chemoresistance of
breast cancer patients [35]. Therefore, BF-rTK +GCV
anti-inflammation effect was helpful for overcoming the
chemoresistance of cancer.
Hopefully, the BF-rTK +GCV system might overcome
drug resistance in single-target drug use in tumor therapy
for its multiple targets and multiple effects. Our study
highlighted the potential of BF-rTK +GCV system for
solid tumor therapy.
Conclusion
BF-rTK +GCV induced tumor apoptosis mediated by
FasL and TNFR2 through the mitochondrial control of
apoptosis via Bid and Bim t does not result in necroptosis
and autophagy. BF-rTK +GCV anti-inflammation effect
was useful for overcoming the chemoresistance of cancer.
Survival analysis results of multiple cancer models con-
firmed that BF-rTK +GCV system has a wide field of
application in solid tumor gene therapy.
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